Both trials involve monoclonal antibodies. Teva’s, Fremanezumab, inhibits the calcitonin gene–related peptide receptor. That from Novartis, Erenumab, targets calcitonin gene–related peptide itself.  Both produce significant improvements in headache frequency, etc,

http://www.nejm.org/doi/full/10.1056/NEJMoa1709038